All News
ICYMI: Evaluation of Bimekizumab in PsA
Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
Read Article
Don’t Buy Guitars (12.6.2024)
This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.
Read Article
Infertility linked to post-childbrith onset of systemic autoimmune disease
d
EurekAlert!
Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a naturally conceived birth compared to women without fertility problems.
Read Article
Challenge in Measuring Cutaneous Lupus Activity and Severity
JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).
Read Article
JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar
- Dx often delayed 6-8 yrs
- Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/UbqVOr2iDx https://t.co/Ye5mYcbYX2
Dr. John Cush RheumNow ( View Tweet)
Fibroblastic Rheumatism - JAMA Case: 50yoM w/ 3 yr hx of periarticular nodules, symmetric polyarthralgia at B/L PIPs. These were painful with manipulation or minor trauma. Labs negative. https://t.co/dWvBjXgAIh https://t.co/YWmdqJrijf
Dr. John Cush RheumNow ( View Tweet)
Primary Hypophosphatemia (HYPOPH) - Japan study 50,136 adults w/ 424,434 alk phosphatase (ALP) tests. Persistent HYPOPH seen in 0.54% (273) due to cancer(30%), steroids(21%), DMARDs (16%). Unexplained HYPOPH had pain, muscle weakness, fatigue & could have primary HYPOPH… https://t.co/kGPSXSYEZI https://t.co/RtwSRnzeU0
Dr. John Cush RheumNow ( View Tweet)
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf
Dr. John Cush RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew
Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/4gujykjDCa https://t.co/RLG1vA57kC
Dr. John Cush RheumNow ( View Tweet)
Novel TYK2 inhibitor Zasocitinib
Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/KbHcgSIohv https://t.co/0g8X4zrq4X
Dr. John Cush RheumNow ( View Tweet)
ACR24 JAK TYK Topic Panel
https://t.co/SzurEICVxr https://t.co/m6cKyA4BBv
Dr. John Cush RheumNow ( View Tweet)
FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease .… https://t.co/ErNWlva9Nd https://t.co/gc8cPNs3H1
Dr. John Cush RheumNow ( View Tweet)
Inebilizumab for Treatment of IgG4-Related Disease
Inebilizumab is a monoclonal antibody that depletes CD19+ B cells and has been studied in adults with IgG4-related disease. In a phase 3, double-blind, randomized, placebo-controlled trial, it reduced IgG4-related disease… https://t.co/7PAmCn9O2I https://t.co/NmNA1p6GmI
Dr. John Cush RheumNow ( View Tweet)
Phase 2b Study of Ianalumab in Sjögren's
A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).
https://t.co/08W0N1f3ap https://t.co/lyZwGI56Qq
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care
MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/94i7NZGSJH https://t.co/XiSLNaLuf9
Dr. John Cush RheumNow ( View Tweet)
Will the Robots Save Ultrasound?
Ultrasound has a lot going for it in rheumatoid arthritis and psoriatic arthritis. It is free of ionizing radiation, yet can deliver helpful insights to the bedside, educating our patients along the way. As we seek to prognosticate more and… https://t.co/2JL2be3RMj https://t.co/4oQy6gcQVS
Dr. John Cush RheumNow ( View Tweet)
JAMA Images in Dermatology - Palmar Fasciitis and Polyarthritis Syndrome -- 50yoM w/ 6 mo. hx of hand/finger swelling, stiffness, thickening, and erythema, impairing mobility. Also found to have hepato-/splenomegaly, WBC 151K, LDH 889; abnl BM Bx. Pt dx w/ palmar fasciitis & CML… https://t.co/1Z9Oz0sRa7 https://t.co/HRSJcv4lzZ
Dr. John Cush RheumNow ( View Tweet)
Full Read Review of the Pulmonary Manifestations in Antisynthetase Syndrome (good reference!) https://t.co/gBLYRmHKE4 https://t.co/pUWmQCHk0N
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA Patient Quiz - Joint Pain in a Woman Wearing a Face Mask https://t.co/fbUERrmzW4 https://t.co/KMJZqsSyMG
Dr. John Cush RheumNow ( View Tweet)
BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/21SHvGyUZH https://t.co/grDr5mfAzn
Dr. John Cush RheumNow ( View Tweet)